| Description: | Prostate cancer is the most common cancer type among men. Some prostate cancers respond to hormonal therapy. However, some cell characteristics of other prostate cancers cause it not to respond as well to these therapies. Researchers want to see if gadoxetate, a contrast agent used to help identify damaged liver tissue, can help tell these types of prostate cancer apart. It may be able to identify if a man has a type of prostate cancer for which hormone therapy may not work as well. |
|---|
| Link: | http://clinicaltrials.gov/ct2/show/NCT01867424 |
|---|---|
| Site | National Cancer Institute |
| Principle Investigator: | Ismail B Turkbey, M.D. |